A5058406768- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- COVID-19 epidemiological studies
- Reproductive System and Pregnancy
- Pregnancy and Medication Impact
- SARS-CoV-2 detection and testing
- COVID-19 Impact on Reproduction
- Multiple Sclerosis Research Studies
- Peripheral Neuropathies and Disorders
- Long-Term Effects of COVID-19
Federico II University Hospital
2022-2023
University of Naples Federico II
2021
Even several months after the start of a massive vaccination campaign against COVID-19, mortality and hospital admission are still high in many countries. Monoclonal antibodies SARS-CoV-2 ideal complement to infected subjects who at risk for progression severe disease. Based on data Italian Ministry Health, period April–August 2021, monoclonal were prescribed 6322 patients. In same period, 70,022 patients over 70 years old became with SARS-CoV-2. considering that all this category patients,...
Despite the lightning-fast advances in management of SARS-CoV after 2 years pandemic, COVID-19 continues to pose a challenge for fragile patients, who could benefit from early administration monoclonal antibodies (mAbs) reduce risk severe disease progression. We conducted prospective study evaluate effectiveness mAbs against SARS-CoV-2 among patients at progression, namely elderly and those with comorbidities, before omicron variant surge. Patients were treated either casirivimab/imdevimab,...
The aim of this study was to report the use casirivimab/imdevimab therapy in pregnant women with moderate coronavirus disease 2019 (COVID-19).
Abstract Despite the lightning-fast advances in management of SARS-CoV after 2 years pandemic, COVID-19 continues to pose a challenge for fragile patients, who could benefit from early administration monoclonal antibodies (mAbs) reduce risk severe disease progression. We conducted prospective study evaluate effectiveness mAbs against SARS-CoV-2 among patients at progression, namely elderly and those with comorbidities, before omicron variant surge. Patients were treated either...
Abstract Even several months after the start of a massive vaccination campaign against COVID-19, mortality and hospital admission are still in considerable numbers many nations. Monoclonal antibodies ideal complement to high-risk subjects who have been infected by SARS-CoV-2 at high risk developing severe disease. Combining data provided clinal trials demographics infections, this analysis tries predict benefits an extensive use monoclonal reduce admissions, deaths, costs.